Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals between the ages of 18-60~2. Meets DSM-5 criteria of current opioid use disorder with six consecutive months of reported heroin use, supported by a positive urine for opiates indicating regular use of heroin~3. Seeking treatment for opioid use disorder with Vivitrol~4. Capable of giving informed consent and complying with study procedures~5. In otherwise good health based on complete medical history and physical examination, laboratory tests, and EKG~6. BMI between 18-40~Exclusion Criteria:~1. Reported treatment with methadone in the last 3 months or positive urine toxicology for methadone on the day of consent~2. Maintenance on, or regular use of buprenorphine or other prescription opioids~3. Pregnancy, lactation, or failure in a sexually active woman to use adequate contraceptive methods.~4. Active medical illness which might make participation hazardous, such as untreated hypertension, acute hepatitis with AST or ALT \> 3 times normal, AIDS (CD4 count under 200 currently or medically ill with an opportunistic infection), unstable diabetes, cardiovascular disease.~5. Active psychiatric disorder which might interfere with participation or make participation hazardous, including DSM-5 Schizophrenia or any psychotic disorder, severe Major Depressive Disorder, or suicide risk or 1 or more suicide attempts within the past year.~6. Physiologically dependent on alcohol or sedative- hypnotics with impending withdrawal. Other substance use diagnoses are not exclusionary.~7. History of allergic or adverse reaction to buprenorphine, naltrexone, naloxone, clonidine, or clonazepam.~8. Chronic neurocognitive disorder~9. History of accidental drug overdose in the last 3 years as defined as an episode of opioid-induced unconsciousness or incapacitation, whether or not medical treatment was sought or received.~10. Painful medical condition that requires ongoing opioid analgesia or anticipated surgery necessitating opioid medications~11. Fentanyl only use, supported by a urine toxicology that is positive for fentanyl only and negative for all other opioids.~12. Court mandated to treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Short-term treatment with buprenorphine (Type: EXPERIMENTAL): Short-term treatment with buprenorphine

Based on this trial design, predict the completion outcome and termination type (if applicable).